Clinical Laboratory Improvement Amendments (CLIA) has not impeded patient access to tests says Office of Inspector General (OIG)
This article was originally published in Clinica
Within the next few months, the US Department of Health & Human Services (HHS) Office of Inspector General (OIG) will announce that strict new rules and federal regulation of clinical laboratories have apparently not limited patient access to certain tests, reports Clinica's Washington correspondent, Duffy Miller.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.